Previsioni

Acquista	5
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028

Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » Altro su finance.yahoo.com
Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028

Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » Altro su de.investing.com
Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million

Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2003, Lineage Cell Therapeutics ha già distribuito 0,0651€ di dividendi. L'ultimo pagamento è avvenuto a dicembre 2003.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Lineage Cell Therapeutics ha registrato ricavi pari a 936,67k€ e un utile netto di 1,30M€

(EUR)	giu 2026	YoY
Ricavi	+936,67k	60,07%
Utile lordo	+772,82k	66,59%
Utile netto	+1,30M	105,02%
EBITDA	+1,52M	137,49%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+241,91M€
Numero di azioni	249,30M
Massimo/minimo a 52 settimane	+1,79€ - +0,86€
Dividendi	No
Beta	1,55
Rapporto P/E	−8,06
Rapporto PEG	+0,20
Rapporto P/B	+4,63
Rapporto P/S	+21,53

Profilo aziendale

Lineage Cell Therapeutics, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt neuartige Zelltherapien zur Behandlung degenerativer Erkrankungen in den Vereinigten Staaten und international. Das Unternehmen entwickelt OpRegen, eine Zellersatztherapie für das retinale Pigmentepithel, die sich in einer klinischen Phase I/IIa-Studie zur Behandlung der trockenen altersbedingten Makuladegeneration befindet; OPC1, eine Oligodendrozyten-Vorläuferzelltherapie, die sich in einer multizentrischen klinischen Phase I/IIa-Studie zur Behandlung akuter Rückenmarksverletzungen befindet; und VAC2, eine allogene Krebsimmuntherapie aus Antigen-präsentierenden dendritischen Zellen, die sich in einer klinischen Phase I-Studie zur Behandlung von nicht-kleinzelligem Lungenkrebs befindet. Das Unternehmen bietet auch Renevia an, ein Produkt für die Gesichtsästhetik. Darüber hinaus beschäftigt sich das Unternehmen mit der Erforschung und Entwicklung von therapeutischen Produkten für Netzhauterkrankungen, neurologische Erkrankungen und Störungen sowie für die Onkologie. Lineage Cell Therapeutics, Inc. hat eine Zusammenarbeit mit Orbit Biomedical, Ltd. Das Unternehmen war früher als BioTime, Inc. bekannt und änderte im August 2019 seinen Namen in Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics, Inc. wurde 1990 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.

Nome	Lineage Cell Therapeutics
CEO	Brian Culley
Sede centrale	Carlsbad, ca Stati Uniti
Sito web	lineagecell.com
Settore	Beni di prima necessità
Industria	Prodotti alimentari
Quotazione in borsa	05/03/1992
Dipendenti	75